Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy

Molecular Cancer Therapeutics

Volumn 13, Issue 2, 2014, Pages 528-539

  Ning, Yan ^a   Gerger, Armin ^b   Zhang, Wu ^a   Hanna, Diana L ^a   Yang, Dongyun ^c   Winder, Thomas ^a   Wakatsuki, Takeru ^a   Labonte, Melissa J ^d   Stintzing, Sebastian ^a   Volz, Nico ^a   Sunakawa, Yu ^a   Stremitzer, Stefan ^a   El Khoueiry, Rita ^a   Lenz, Heinz Josef ^a,c  

^a Division of Medical Oncology   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d AZUSA PACIFIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; ANTINEOPLASTIC AGENT; FLUOROURACIL; LCP1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PLASTIN;

ADJUVANT CHEMOTHERAPY; AGED; ALLELE; CANCER STAGING; COLONIC NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICROFILAMENT PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894127680     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0646     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085-91.
3. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196-206.
4. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: integrating signals from front to back. Science. 2003;302:1704-9.
5. Samstag Y, Eibert SM, Klemke M, Wabnitz GH. Actin cytoskeletal dynamics in T lymphocyte activation and migration. J Leukoc Biol. 2003;73:30-48.
6. Giganti A, Plastino J, Janji B, Van Troys M, Lentz D, Ampe C, et al. Actin-filament cross-linking protein T-plastin increases Arp2/3-mediated actin-based movement. J Cell Sci. 2005;118:1255-65.
7. Park T, Chen ZP, Leavitt J. Activation of the leukocyte plastin gene occurs in most human cancer cells. Cancer Res. 1994;54:1775-81.
8. Lin CS, Lau A, Yeh CC, Chang CH, Lue TF. Upregulation of L-plastin gene by testosterone in breast and prostate cancer cells: identification of three cooperative androgen receptor-binding sequences. DNA Cell Biol. 2000;19:1-7.
9. Lin CS, Chen ZP, Park T, Ghosh K, Leavitt J. Characterization of the human L-plastin gene promoter in normal and neoplastic cells. J Biol Chem. 1993;268:2793-801.
10. Willis ND, Cox TR, Rahman-Casans SF, Smits K, Przyborski SA, van den Brandt P, et al. Lamin A/C is a risk biomarker in colorectal cancer. PLoS ONE. 2008;3:e2988.
11. Foran E, McWilliam P, Kelleher D, Croke DT, Long A. The leukocyte protein L-plastin induces proliferation, invasion and loss of E-cadherin expression in colon cancer cells. Int J Cancer. 2006;118: 2098-104.
12. Klemke M, Rafael MT, Wabnitz GH, Weschenfelder T, KonstandinMH, Garbi N, et al. Phosphorylation of ectopically expressed L-plastin enhances invasiveness of human melanoma cells. Int J Cancer. 2007; 120:2590-9.
13. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011;128:2038-49.
14. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011;17:6934-43.
15. Absenger G, Benhaim L, Szkandera J, Zhang W, Yang D, Labonte MJ, et al. The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5- FU-based chemotherapy. Pharmacogenomics J. 2013 Apr 9. [Epub ahead of print].
16. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res. 2008;36: D820-4.
17. Lee PH, Shatkay H. An integrative scoring system for ranking SNPs by their potential deleterious effects. Bioinformatics. 2009;25:1048-55.
18. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92:965-70.
19. Cardiff RD. Epithelial to mesenchymal transition tumors: fallacious or snail's pace? Clin Cancer Res. 2005;11:8534-7.
20. Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin. 2008;40:643-50.
21. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol. 2005;17:499-508.
22. Junghans D, Haas IG, Kemler R. Mammalian cadherins and protocadherins: about cell death, synapses, and processing. Curr Opin Cell Biol. 2005;17:446-52.
23. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469-80.
24. Hulsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol. 1994;127:2061-9.
25. Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013;73:2059-69.
26. Lapillonne A, Coue O, Friederich E, Nicolas A, Del Maestro L, Louvard D, et al. Expression patterns of L-plastin isoformin normal and carcinomatous breast tissues. Anticancer Res. 2000;20: 3177-82.
27. Li MX, Xiao ZQ, Liu YF, Chen YH, Li C, Zhang PF, et al. Quantitative proteomic analysis of differential proteins in the stroma of nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissue. J Cell Biochem. 2009;106:570-9.
28. Samstag Y, Klemke M. Ectopic expression of L-plastin in human tumor cells: diagnostic and therapeutic implications. Adv Enzyme Regul. 2007;47:118-26.
29. Li J, Zhao R. Expression and clinical significance of L-plastin in colorectal carcinoma. J Gastrointest Surg. 2011;15:1982-8.
30. Hao Y, Yu Y, Wang L, Yan M, Ji J, Qu Y, et al. IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J Proteome Res. 2008;7:3668-77.
31. Hisano T, Ono M, Nakayama M, Naito S, Kuwano M, Wada M. Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: identification by mRNA differential display. FEBS Lett. 1996;397:101-7.
32. Higuchi Y, Kita K, Nakanishi H, Wang XL, Sugaya S, Tanzawa H, et al. Search for genes involved in UV-resistance in human cells by mRNA differential display: increased transcriptional expression of nucleophosmin and T-plastin genes in association with the resistance. Biochem Biophys Res Commun. 1998;248:597-602.